All In Biotech

Drug Trial Radar · NCT07930767

Phase I Trial of RBD4059 in Chinese Healthy Participants

A Randomized, Double-Blind, Sponsor-Open, Placebo-Controlled Phase I Trial to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Single Doses of Subcutaneously Administered Vortosiran (RBD4059) in Chinese Healthy Participants

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Dec 2026

Primary completion

Aug 2027

Study completion Dec 2027

Sponsor

Sponsor type
Industry
First posted
Nov 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, sponsor-open, placebo-controlled, single-dose phase I study. The goal of this clinical trial is to evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and tolerability of RBD4059 in Chinese healthy participants. Participants will receive single doses of RBD4059 or placebo, and need about 16 visits for checkups and tests until End of trial.

Conditions

  • Healthy

Interventions

  • RBD4059Drug

    Subcutaneously Administered RBD4059 in Healthy Participants.

  • PlaceboDrug

    Subcutaneously Administered Placebo in Healthy Participants.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Plasma concentrations of RBD4059Time frame: Until 48 hours after injection
  2. PharmacodynamicsTime frame: Until Day 169

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.